R&D
On genomics, NGS, and doing much more good than bad, with Ma...
Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
News
Ipsen licenses Simcere ADC in $1bn-plus deal
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
News
AZ's ATR inhibitor ceralasertib flunks lung cancer test
AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
R&D
Beyond good intentions: How life sciences can prove its read...
While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.
R&D
Q4 Clinical trials round-up: October to December 2025
We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
